Marketwire -- London, UK; Brentwood, TN, US: 3 September 2008 - Protherics PLC
("Protherics" or the "Company"), the international biopharmaceutical
company focused on critical care and cancer, announces that on 2
September 2008, in accordance with the Transparency Obligations
Directive, a notification of interest in the ordinary share capital of
the Company was received from Citigroup on behalf of Standard Life
Investments Ltd. Details of the interest notified are as follows:
